Dr Long, professor of medicine at the University of North Carolina at Chapel Hill, discusses her presentation at the Advances in Inflammatory Bowel Disease 2020 virtual meeting on how data from both clinical trials and real-world practice can help clinicians make the best choices for therapies for their patients with IBD.
Clearly communicating the findings of endoscopy to pathologists, colleagues, and patients requires some standardization in the preparation of endoscopic reports, David T. Rubin, MD, told the attendees of the Advances in Inflammatory Bowel Diseases 2020 virtual meeting on December 11.
Anne Griffiths, MD, of the Hospital for Sick Children in Toronto, spoke to the Advances in Inflammatory Bowel Diseases 2020 virtual meeting on research published this year into the special considerations involved in caring for children with Crohn disease and ulcerative colitis.
Dr Kane, professor of medicine at the Mayo Clinic in Rochester, Minnesota, reviews her presentation at the AIBD 2020 virtual meeting on how best to inform and educate patients with inflammatory bowel disease to help ensure good outcomes.
In this video, Dr. Dubinsky, codirector of the Susan and Leonard Feinstein IBD Center at the Icahn School Medicine at Mount Sinai in New York, reviews a panel discussion on therapeutic monitoring of anti-TNF levels in patients with inflammatory bowel disease, presented December 11 at AIBD 2020.
In this video, Dr Kornbluth, of the Icahn School of Medicine at Mount Sinai in New York, reviews his presentation from AIBD 2020 on the importance of careful surveillance for dysplasia and follow-up with patients with inflammatory bowel disease.
Dr Abreu, director of the Crohn's and Colitis Center at the University of Miami Miller School of Medicine, reviews her presentation from the AIBD 2020 virtual meeting on applying precision medicine today and in the future in the practice of caring for patients with inflammatory bowel disease.
Updates to the SECURE-IBD international registry indicate that thiopurines and combination therapies may place patients with inflammatory bowel disease at heightened risk of poor outcomes from COVID-19, while anti-tumor necrosis factor agents may be protective.
In this video, Dr Siegel, from Dartmouth-Hitchcock Medical Center, reviews his presentation from the Advances in Inflammatory Bowel Diseases 2020 virtual meeting on applying professional guidelines in real-world gastroenterology practice.
Dr Mahadevan, from the University of California at San Francisco, spoke at the Advances in Inflammatory Bowel Disease 2020 virtual meeting on the ongoing 13-year PIANO study designed to assess the outcomes of pregnant women with IBD and their children, up to the age of 4 years.